share_log

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

inmed pharmaceuticals为INm-901在治疗包括阿尔茨海默病在内的神经退行性疾病提交了额外的专利申请
newsfile ·  10/28 07:30

Vancouver, British Columbia--(Newsfile Corp. - October 28, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that it has filed an additional international patent application, under the Patent Cooperation Treaty (PCT), focused on the pharmaceutical composition and method of use for the proprietary small molecule drug candidate INM-901 for treating neurodegenerative diseases, including Alzheimer's disease.

温哥华,不列颠哥伦比亚省-(资讯稿 - 2024年10月28日)- inmed pharmaceuticals股份有限公司(纳斯达克:INM)("InMed"或"该公司"),一家专注于开发一系列私有小分子药物候选药物管道以治疗医疗需求尚未得到满足的疾病的制药公司,宣布已根据专利合作条约(PCT)提交了一项额外的国际专利申请,重点放在专有小分子候选药INm-901的制药组合和使用方法上,用于治疗神经退行性疾病,包括阿尔茨海默病。

This PCT patent application encompasses several key components, including:

该PCT专利申请涵盖了几个关键元件,包括:

  • treatment of neuronal disorders, particularly those associated with neurodegeneration;
  • potential to inhibit or slow the progression of neurodegenerative diseases by reducing cytotoxicity in affected neuron populations; and
  • use in promoting neurite elongation and/or restoring neurite formation in damaged neurons.
  • 治疗神经元紊乱,特别是与神经退化相关的疾病;
  • 潜力抑制或减缓神经退行性疾病的进展,通过减少受影响神经元人群中的细胞毒性;
  • 用于促进受损神经元的神经突触延长和/或恢复神经突触形成。

Additionally, the patent application specifies methods for neuroprotection, stimulating neurogenesis, enhancing basal and locomotor activity, improving anxiety-related behaviors, cognitive function, memory, and sound awareness, as well as downregulating inflammation markers and upregulating neuronal function markers.

此外,专利申请规定了神经保护、刺激神经发生、增强基底和运动活动、改善与焦虑相关的行为、认知功能、记忆和声音意识,以及调降炎症标志物和上调神经功能标志物的方法。

"The INM-901 drug development program represents a novel approach to treating Alzheimer's disease and the conversion of this PCT application is an important step to protect our research and development in the area of neurodegeneration," stated Dr. Eric Hsu, Senior Vice President of Preclinical Research & Development at InMed. "We have recently made significant progress with the INM-901 and are committed to advancing this program towards human clinical trials. We look forward to presenting long-term in vivo data in the coming weeks."

“INm-901药物开发计划代表了一个治疗阿尔茨海默病的新方法,此PCt申请的转化是保护我们在神经退行领域中研发的重要一步,”InMed的临床前研究与开发高级副总裁Eric Hsu博士表示。“我们最近在INm-901项目中取得了重大进展,并致力于推进该项目朝着人类临床试验迈进。我们期待在未来几周内展示长期的体内数据。”

This development further enhances InMed patent portfolio which currently includes fourteen patent families, eight of which focus on drug composition/formulations/methods of use and six address manufacturing technologies.

这一进展进一步增强了InMed目前拥有的专利组合,其中包括十四个专利家族,其中八个侧重于药物组成/配方/使用方法,六个涉及制造技术。

INM-901: Targeting several biological pathways associated with Alzheimer's disease

INm-901:针对与阿尔茨海默症相关的多种生物途径。

INM-901 is a proprietary small molecule drug candidate with multiple mechanisms of action as a potential treatment for Alzheimer's disease. Key characteristics of INM-901 include:

INm-901是一种专有小分子药物候选,具有多种可能作为治疗阿尔茨海默病的作用机制。INm-901的关键特征包括:

  • demonstrates reduced neuroinflammation and improved neurite growth and neuronal function, indicating the potential to restore damage caused by Alzheimer's disease;
  • is a preferential signaling agonist of the CB1/CB2 receptors and has been shown to have neuroprotective effects, helping protect the neurons in the brain from damage and cell death;
  • impacts the peroxisome proliferator-activated receptors ("PPARs"), which have been shown to play an important role in diabetes and are also considered as one of the potential therapeutic targets for neurodegenerative disorders such as Alzheimer's disease;
  • can be administered orally and achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal injection, offering many potential advantages over routes of administration of the currently approved products; and
  • demonstrates significant improvement in cognitive function, memory, locomotor activity, anxiety-based behavior and sound awareness in long-term preclinical behavioural studies.
  • 显示出降低神经炎症和改善神经突起生长以及神经元功能,表明有潜力恢复阿尔茨海默病造成的损害;
  • 是CB1/CB2受体的优先信号激动剂,并且显示出具有神经保护作用,有助于保护大脑中的神经元免受损害和细胞死亡;
  • 影响过氧化物酶体增殖激活受体("PPARs"),已显示在糖尿病中扮演重要角色,并被认为是治疗神经退行性疾病如阿尔茨海默病的潜在治疗靶点之一;
  • 可口服给药并在大脑中达到与腹腔内注射相当的治疗水平,相比当前批准的产品的给药途径,具有许多潜在优势;并
  • 在长期的临床前行为研究中,显示出认知功能、记忆、运动活动、基于焦虑的行为和声音意识方面的显著改善。

About InMed:

关于InMed:

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit .

inmed pharmaceuticals是一家专注于开发以CB1/CB2受体为靶点的专有小分子药物候选品管线的制药公司。InMed的管线包括三个独立项目,用于治疗阿尔茨海默病、眼科和皮肤科指示。欲了解更多信息,请访问。

Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1 604 416 0999
E: ir@inmedpharma.com

投资者联系人:
Colin Clancy
投资者关系副总裁
和企业通讯
电话号码:+1 604 416 0999
E: ir@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:

有关前瞻性信息的注意事项:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about; filing an additional patent application for INM-901; What the new patent encompasses; the efficacy of INM-901, INM-901's ability to treat AD, marketability and uses for INM-901, the results of further studies into INM-901 and acceleration of the development of InMed's AD program as well as potential GLP studies or IND submissions.

本新闻发布包含“前瞻性信息”和“前瞻性陈述”(统称为“前瞻性信息”),在适用证券法律的意义内。前瞻性陈述经常但并非总是通过诸如“预计”,“预期”,“相信”,“打算”,“潜在”,“可能”,“将”等类似表达来识别。此类声明是基于管理层对当前预期的立场,固有地涉及众多风险、不确定因素和假设,已知和未知的,其中许多超出我们的控制范围。前瞻性信息基于管理层当前的期望和信念,受到许多风险和不确定性的影响,这可能导致实际结果与前瞻性陈述中描述的有实质不同。在不限制前述内容的前提下,本新闻发布中的前瞻性信息包括但不限于有关以下内容的声明;为INm-901提交额外专利申请;新专利包含的内容;INm-901的疗效,INm-901治疗AD的能力,INm-901的市场可行性和用途,有关进一步研究INm-901和加速InMed的AD项目开发以及潜在的GLP研究或IND提交的结果。

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.

此外,已知和未知的风险因素可能会导致InMed的实际结果、表现或成就与这里所包含的前瞻性信息未来的结果、表现或成就存在实质性的差别。关于InMed的独立业务所面临的所有风险和不确定因素的完整讨论已在InMed的年报10-K表和其他提交给www.sec.gov的证券交易委员会的文件中披露。

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

此处所有的前瞻性信息都受到这一警示声明的限制,并且InMed放弃了对任何此类前瞻性信息进行修订和更新或公开宣布任何对此类前瞻性信息所做修订的结果来反映未来的结果、事件或发展的义务,除非法律要求其这样做。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发